Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET

PURPOSE: Almost all radiolabellings of antibodies with (89)Zr currently employ the hexadentate chelator desferrioxamine (DFO). However, DFO can lead to unwanted uptake of (89)Zr in bones due to instability of the resulting metal complex. DFO*-NCS and the squaramide ester of DFO, DFOSq, are novel ana...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur J Nucl Med Mol Imaging
Main Authors: Chomet, Marion, Schreurs, Maxime, Bolijn, Maria J., Verlaan, Mariska, Beaino, Wissam, Brown, Kari, Poot, Alex J., Windhorst, Albert D., Gill, Herman, Marik, Jan, Williams, Simon, Cowell, Joseph, Gasser, Gilles, Mindt, Thomas L., van Dongen, Guus A. M. S, Vugts, Danielle J.
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8036225/
https://ncbi.nlm.nih.gov/pubmed/32889615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-05002-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares